Skip to content
IRONXPEPTIDES
GHK-CU 50MG research vial, Iron Peptide Research label
Skin & Cosmetic

GHK-Cu

Also known as Copper tripeptide-1, Glycyl-L-histidyl-L-lysine copper(II)

GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide found in human plasma. It is studied for effects on fibroblasts, collagen synthesis, wound healing and skin remodeling, and is used as a cosmetic ingredient.

Clinical-stage research

Size

2 options
Catalog no.
CU
Specification
50mg*10vials
Per kit
10 vials
PricePricing will be published soon

For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.

Overview

GHK was identified by Loren Pickart in 1973 as a factor in human plasma that prolonged survival of normal liver cells in culture, and was later shown to bind copper(II) with high affinity. The GHK sequence also occurs within extracellular matrix proteins, from which it may be released during tissue injury. Laboratory work has examined its effects on collagen, glycosaminoglycans, matrix metalloproteinases and gene expression. A multicenter controlled trial in the 1990s tested a GHK-Cu formulation in diabetic foot ulcers. GHK-Cu is widely used in cosmetic formulations but is not an approved drug.

Class: Copper-binding tripeptide

Mechanism of action

How the compound acts, as described in the literature.

  1. Forms a high-affinity complex with copper(II) and is proposed to act partly by modulating copper availability to cells and to copper-dependent enzymes involved in matrix formation.

  2. In fibroblast cultures, it stimulated collagen synthesis at picomolar to nanomolar concentrations without changing cell number; other studies report effects on glycosaminoglycan and decorin production.

  3. Reported to modulate matrix metalloproteinases and their tissue inhibitors, consistent with a role in extracellular matrix remodeling during wound repair.

  4. Analyses of gene-expression databases suggest GHK is associated with expression changes in many human genes, a hypothesis-generating finding that has not been tested in controlled studies.

Published research

Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.

Evidence & safety

What the research does not show, and the adverse events and regulatory status it reports.

Human evidence is limited to a 1994 diabetic ulcer trial and small cosmetic studies, and no large controlled trials have been published since. Gene-expression findings are computational and hypothesis-generating. GHK-Cu is a cosmetic ingredient, not an approved drug; the studies reviewed report no specific safety signals, but systematic safety data are lacking.

Specifications

All sizes, exactly as catalogued.

Catalog no.ProductSpecificationVials per kit
CUGHK-Cu50mg*10vials10
CU100GHK-Cu100mg*10vials10

For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.

More in Skin & Cosmetic